Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian equity markets remain lackluster
Thu, 30 May 01:30 pm

Indian equity markets recovered some losses in last two hours of trade, though they hovered around the dotted line. Barring auto, FMCG and power sectors, all the sectoral indices are trading in the negative territory. Realty and Oil & gas stocks are witnessing maximum selling pressure.

BSE-Sensex is down by 12 points and NSE-Nifty is trading down by 8 points. While BSE Mid Cap is trading up by 0.05%, BSE Small Cap index is trading down by 0.25%. The rupee is trading at 56.19 to the US dollar.

Majority of the telecom stocks are trading in the red with Tata Tele and MTNL among the major losers. As per a leading financial daily, the Communications Minister has given a go-ahead for imposing a Rs 6.5 bn penalty on Bharti Airtel for providing subscriber local dialing (SLD) services in 13 regions during the period 2003-2005. SLD allows roaming customers to remain on the local network and skip roaming and STD charges. In June 2003, the Telecom Ministry had directed Bharti Airtel to stop providing SLD facility as it amounted to violation in the national routing plan. However as per Ministry officials, the company continued offering this service till 2005. This development is expected to further compound Bharti Airtel's woes as the company is already facing penalties for a host of alleged violations. The company's stock is currently down 1.6%.

Domestic pharma stocks are trading mixed with, Ipca Labs and Dishman Pharma trading firm while Cipla Ltd and Piramal Enterprises are trading weak. As per a financial daily, a US Congress member is seeking to review USFDA's (United States Food and Drugs Administration) probe into Ranbaxy. Steve Israel is a member of the US Congress. He has sent letter to the office of inspector general at the US department of health and human services asking for a complete review of the USFDA's actions during last 8 years. The letter calls to review the USFDA oversight policies and what steps can be taken by authorities to improve such events in the future. The letter also suggested for a complete review of the USFDA'S oversight of pharmaceutical drugs manufactured in foreign facilities. Earlier this month, Ranbaxy had pleaded guilty on various counts of federal and civil charges. The company had also agreed to pay a fine of US$ 500 m in order to settle the claims with the US Department of Justice. Ranbaxy was trading up by 0.12%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian equity markets remain lackluster". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.